UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Clinical cancer research, 2016-11, Vol.22 (22), p.5461-5471

2016

Volltextzugriff (PDF)

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting

PloS one, 2015-04, Vol.10 (4), p.e0120877

2015

Volltextzugriff (PDF)

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

Oncoimmunology, 2018-09, Vol.7 (9), p.e1476816-e1476816

2018

Volltextzugriff (PDF)

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

European urology, 2021-08, Vol.80 (2), p.162-170

2021

Volltextzugriff (PDF)

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial

European journal of cancer (1990), 2021-03, Vol.145, p.1-10

2021

Volltextzugriff (PDF)

Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia

Cancer, 2018-02, Vol.124 (3), p.499-506

2018

Volltextzugriff (PDF)

Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive

Translational andrology and urology, 2017-10, Vol.6 (5), p.839-847

Fishman, Mayer N

2017

Volltextzugriff (PDF)

Targeted therapy of kidney cancer: keeping the art around the algorithms

Cancer control, 2013-07, Vol.20 (3), p.222-232

Fishman, Mayer N

2013

Volltextzugriff (PDF)

Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study

Cardiovascular and interventional radiology, 2021-11, Vol.44 (11), p.1755-1762

2021

Volltextzugriff (PDF)

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

Clinical genitourinary cancer, 2022-02, Vol.20 (1), p.1-10

2022

Volltextzugriff (PDF)

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer

Cancer control, 2013-01, Vol.20 (1), p.7-16

2013

Volltextzugriff (PDF)

Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma

Cancer control, 2010-10, Vol.17 (4), p.269-278

2010

Volltextzugriff (PDF)

Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma

Canadian journal of urology, 2015-08, Vol.22 (4), p.7882

2015

Volltextzugriff (PDF)

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the adaptive abiraterone (abi) study (NCT02415621)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5041-5041

2019

Volltextzugriff (PDF)

Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines

Expert opinion on pharmacotherapy, 2007-12, Vol.8 (17), p.2979-2990

2007

Volltextzugriff (PDF)

Microbial metabolism of tryptophan is associated with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4564-4564

2023

Volltextzugriff (PDF)

Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.312-312

2019

Volltextzugriff (PDF)

High-dose bolus interleukin-2: Correlating response rate with number of doses received

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.452-452

2013

Volltextzugriff (PDF)

Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5080-5080

2020

Volltextzugriff (PDF)

A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.685-685

2020

Volltextzugriff (PDF)

Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4553-4553

2016

Volltextzugriff (PDF)

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS2649-TPS2649

2019

Volltextzugriff (PDF)

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.388-388

2019

Volltextzugriff (PDF)

Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.657-657

2019

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(80)
Buchkapitel
(2)

Sprache

Englisch
(82)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(18)
Oncology
(14)
Renal Cell Carcinoma
(12)
Kidney Neoplasms - Pathology
(7)
Male
(7)
Immunotherapy
(6)
Kidney Cancer
(6)
Kidney Neoplasms - Drug Therapy
(6)
Kidney Neoplasms - Therapy
(6)
Nccn Clinical Practice Guidelines
(6)
Neoplasm Staging
(6)
Antineoplastic Agents - Therapeutic Use
(5)
Carcinoma, Renal Cell - Pathology
(5)
Carcinoma, Renal Cell - Therapy
(5)
Patients
(5)
Prognosis
(5)
Cancer
(4)
Carcinoma, Renal Cell - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial

Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia

Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive

Targeted therapy of kidney cancer: keeping the art around the algorithms

Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer

Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma

Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the adaptive abiraterone (abi) study (NCT02415621)

Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines

Microbial metabolism of tryptophan is associated with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC)

Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer

High-dose bolus interleukin-2: Correlating response rate with number of doses received

Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study

A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)

Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC)

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02

Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial

Aktive Filter

Suchergebnisse filtern